Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0917801 (insomnia)
 10,606 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

It is estimated that there are approximately six million patient-years of clinical experience with fenofibrate among physicians outside of the United States. A review of the European literature and unpublished studies supplied by the manufacturer (Laboratoires Fournier, Dijon, France) has been compiled with the data recently reported from a double-blind, placebo-controlled study completed in the United States. In general, fenofibrate has been found to reduce serum triglyceride levels by 30 to 60 percent in patients with type II B and IV hyperlipoproteinemia. Serum cholesterol levels were also reduced by 20 to 25 percent in this group of hypertriglyceridemic patients. A similar reduction in serum cholesterol levels was also found in type II A patients (normal triglyceride levels). Low-density lipoprotein levels were usually reduced in those patients with elevated levels and high-density lipoprotein levels increased when baseline levels were low. Fenofibrate also produced a 10 to 28 percent reduction in uric acid that was sustained for years. The incidence of unwanted effects ranged from 2 to 15 percent in the open trials lasting from a few months up to six years. Gastrointestinal problems (abdominal discomfort, diarrhea, and constipation) are most common, occurring in approximately 5 percent of patients. Reports including fatigue, headache, loss of libido, impotence, dizziness, and insomnia were grouped as neurologic and occurred with a total incidence of 3 to 4 percent. In about 1 percent of patients, muscle tenderness developed, often accompanied by elevated creatine phosphokinase levels. These and the gastrointestinal problems occurred with a similar frequency in the placebo-treated cohort in controlled studies. In approximately 2 percent of patients, a skin rash developed, an incidence that appears significantly higher than that of placebo control groups. Liver changes in rodents have included marked peroxisome proliferation and increased hepatic carcinomas with very high doses. In humans, only a small increase in incidence of elevated levels of serum glutamic oxaloacetic transaminase and serum glutamic pyruvic transaminase seems to be present and is not clearly different from that of the control groups. Alkaline phosphatase, gamma-glutamyl transferase, and bilirubin levels are often decreased with no known undesirable effects. Investigations into the lithogenicity of bile indicated a significant increase in five studies. However, there has been no evidence of a significant rise in the incidence of cholelithiasis in the clinical trials completed to date.
 ...
PMID:Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives. 331 50

Health effects of occupational exposure to lead were investigated among 92 exposed workers in lead-acid battery factory and 40 nonexposed workers serving as a control group from an oil mill in Khartoum North industrial area. The two groups were closely similar in age, stature, body weight, and socioeconomic conditions. A highly significant increase (P less than .01) was recorded in blood lead, urinary coproporphyrin, and basophilic stippled red blood cells of the exposed group in comparison to the control group. Central nervous system symptoms (insomnia, fatigue, weakness, and drowsiness) were reported by 50% and other symptoms such as abdominal colic and constipation were reported by 41% of the exposed group. Blue line on the gum was detected only on 2% of the exposed group. Strong associations between exposure to lead and the prevalence of central nervous system symptoms, abdominal colic, and constipation were recorded. Exposure to exceedingly high levels of lead in the working environment causes adverse health effects.
 ...
PMID:Effects of exposure to lead among lead-acid battery factory workers in Sudan. 376 35

This paper presents results from a study which examined the occurrence and time course of smoking withdrawal symptoms in a group of 33 smokers followed over a 21 day period of abstinence. Smoking withdrawal symptoms examined included: irritability, feeling sleepy, sleeplessness, dizziness, coughing, tightness in the chest, constipation, mouth sores, and cravings for a cigarette. Findings showed a fairly consistent pattern of reduction across days of abstinence for six of the nine symptoms examined--irritability, feeling sleepy, dizziness, coughing, tightness in the chest, and cravings. Most symptoms decreased sharply during the first few days of cessation followed by a continued, but slower rate of decline in the second and third week of abstinence. Heavy smokers tended to report more withdrawal symptoms than light smokers, although the difference between heavy and light smokers was statistically significant only with respect to irritability. The implications of these findings for relapse prevention are discussed.
 ...
PMID:Reports of smoking withdrawal symptoms over a 21 day period of abstinence. 409 Oct 70

The clinical efficacy and safety of timiperone, a new butyrophenone derivative, on chronic schizophrenia was compared with clocapramine by the double-blind method using a total of eighty-eight patients, consisting of forty-four patients in each group. In the final global improvement rating, the global improvement rating in each week and the general usefulness rating, there were no statistically significant differences between the two groups. However, in the global improvement rating in each symptom, timiperone was significantly superior to clocapramine in delusion and showed a superior tendency to clocapramine in contact. Timiperone showed a higher improvement rate than clocapramine in hallucination and disturbance of self-consciousness. In the over-all safety rating, there were no significant differences between the two groups, but in accompanying symptoms and side-effects, timiperone showed significantly less tendency than clocapramine in dyskinesia, insomnia, constipation and nausea. From these results, including the analysis by stratification, it was considered that timiperone was a superior or equivalent neuroleptic in comparison with clocapramine against the negative symptoms as well as the positive ones of chronic schizophrenia, and was equally safe or safer than clocapramine.
 ...
PMID:Comparison of efficacy of timiperone, a new butyrophenone derivative, and clocapramine in schizophrenia: a multiclinic double-blind study. 613 17

To assess sex-related differences, 53 inpatients with major depression were evaluated with the Zung, Dempsey , and Hamilton depression scales, and part of the Beck scale. Women had more fitful sleep, easy crying, social withdrawal, agitation, somatic anxiety, gastrointestinal symptoms, genital symptoms, crying spells, constipation, and fast heartbeat. Men had more self-dislike and lack of clear mind. Differences in manifestations of major depression may account for misdiagnosis of female depressives as suffering from anxiety or functional insomnia and lead to treatment with anxiolytics rather than antidepressants. Self-dislike and mental clouding may lead male depressives to serious suicide attempts and work failures.
 ...
PMID:Sex differences in inpatients with major depression. 614 72

Three double-blind, placebo controlled studies found isocarboxazid (40-50 mg/day) to be efficacious and safe for the treatment of atypical depression. The few instances of liver function elevations were generally borderline; one patient had a marked increase of both SGOT and SGPT (with normal bilirubin and alkaline phosphatase) at Week 6 which normalized over the next several months. Another patient had a mild, temporary hypertensive reaction after eating cheese but did not require any treatment alterations. Drops in both systolic and diastolic blood pressures, as well as orthostatic changes, were common but generally mild and well-tolerated. The most frequently noted side effects were dizziness, headache, dry mouth, insomnia, and constipation. Clinical adverse reactions tended to be mild and to respond to dosage decreases. Isocarboxazid appears to be an underutilized and potentially valuable agent for the treatment of depressed patients.
 ...
PMID:Side effects of isocarboxazid. 637 85

This article discusses the current and potential use of paradoxical interventions in behavioral medicine. Paradoxical interventions are considered to be of two types: intra-individual and interpersonal. Treatment indications differ for the two types of interventions. Intraindividual paradoxical interventions have been successful in the treatment of insomnia, psychogenic urinary retention and constipation. Interpersonal paradoxical interventions have been subjected to less empirical research, but have been useful in the treatment of anorexia nervosa and in family based interventions where medical patients maladaptively cope with their rehabilitation. Paradoxical procedures are also used in the treatment of sexual dysfunction and may be of value in pain management. Further possible applications as well as limitations of paradoxical interventions in behavioral medicine are discussed.
 ...
PMID:Paradoxical interventions in behavioral medicine. 649 Sep 30

A double-blind randomized study was performed in 86 depressed out-patients, in order to compare the efficacy and tolerance of mianserin (30 to 60 mg daily) with that of nortriptyline (75 to 150 mg daily). Both drugs were administered for 6 weeks after a wash-out period of 1 week. The Hamilton Rating Scale for Depression was used weekly and the Clinical Global Impression Scale at the end of treatment. Both preparations proved to be effective, with no significant differences in response. However, tolerance in the mianserin group was much better than in the nortriptyline group. Significant differences were found mainly in the incidence and severity of tachycardia, dry mouth, constipation, sweating, insomnia, agitation and oedema.
 ...
PMID:The clinical efficacy and side-effects of mianserin and nortriptyline in depressed out-patients: a double-blind randomized trial. 675 61

The data presented in this paper examine the frequent statements that the regular use of the drug qat by the people of North Yemen is harmful to their health. The research strategy employed performance of blind physical examinations as well as extensive interviews with 335 females and 371 males in and around the cities of Sanaa, Taiz and Hodeida who had been selected using a quota sample. The sample was classified into heavy, light and non-chewers of the qat plant, and systematic comparisons were made. In general, few diseases or conditions occurred with enough frequency to permit detailed analysis and fewer yet were associated with qat-use. Where associations occurred, differences by sex were often strong. Conditions most strongly associated with use by both sexes were histories of gastritis and insomnia, and the general body system groupings of gastrointestinal disorders. In males the strongest associations were with the histories of anorexia, constipation, insomnia and headaches, as well as the general history of respiratory difficulties. In females strong associations were seen between qat-use and the diagnosis of acute gastritis, and histories of jaundice, bronchitis and hepatic diseases. When effects of age and residence were corrected for by Mantel-Haenszel odds ratios on these items, some of the associations were diminished even further. In general, remarkably few of the allegations regarding the direct effects of qat-use on health by Western visitors to Yemen were supported by this study.
 ...
PMID:A medical evaluation of the use of qat in North Yemen. 687 37

Encouraged by the good results obtained using acupuncture anaesthesia, we started therapeutic acupuncture in our institute of anaesthesiology four years ago. In the meantime acupuncture is as important a therapeutic method in our out-patients department as are therapeutic local anaesthesia, transcutaneous electrical nerve stimulation and biofeedback. The results in 520 patients who have been treated with acupuncture for different diseases are reported. The success of treatment, the number of sessions and the recurrence-rate within one and a half years are discussed for the different diseases. Acupuncture treatment was regarded successful when 1, the patient had no complaints at all without medication, and 2, when there was significant improvement (no long term medication, only mild complaints with unusual strain, which were responsive to minimal medication). Thus treatment in cephalgia was successful in 83% with no recurrences (NR) in 84%. In cervical pain syndromes the respective percentages were 80% (NR = 74%) in constipation 80% (NR = 72%), sinusitis 86% (NR = 100%), insomnia 100% (NR = 100%). Good results, albeit with high recurrence rate were achieved in cases of trigeminal neuralgia in 90% (NR = 23%), colitis ulcerosa in 100% (NR = 0%), in bronchial asthma 70% (NR = 50%) and in tumour pain 61% (NR = 0%). Treatment in patients suffering from parathymic conditions were unsatisfactory and results in cases of tinnitus were negative.
 ...
PMID:[Acupuncture therapy in the outpatients-department of the University Clinic Heidelberg (author's transl)]. 697 22


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>